The company, which is building the world’s largest multi-ethnic Asia-centric microbiome repository of data and samples, said the funding round was also backed by new investors, including Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7, and SEEDS Capital.
Microbiome is the collection of all microbes, such as bacteria, fungi, virus, and their genes that naturally live on human bodies. AMILI, through its proprietary analytics engine, AMILI PRIME, develops diagnostics tests, predictive algorithms, and microbiome-modifying interventions.
Since its inception, AMILI said it has established more than 20 research studies across a wide range of health indications, with a total grant value exceeding S$60 million. It is the only FMT provider in Southeast Asia, serving the region’s 680 million people.
The company has three core assets that allow it to create and capture value: a multi-ethnic Asia microbiome database; a microbiome bank with samples stored for metagenomic and metabolomic analysis; and AMILI PRIME, a set of proprietary analytical tools, informatics pipelines, and discovery engines.
AMILI said the funding strengthens its position as Southeast Asia’s largest precision gut microbiome company. The round, it added, was carefully constructed to bring onboard investors with expertise from the biotechnology, healthcare, and food technology sector.
The fresh funds will be used to accelerate the company’s business expansion in Southeast Asia and Greater Asia. It also seeks to boost its microbiome research partnerships and further develop AMILI PRIME.
“Although gut health research has advanced steadily over the years in other regions, there is still a big gap in research that is representative of the Asian population,” said Tommy Teo, managing director of Vulcan Capital, the lead investor in the funding round.